Stock LADX LADRX CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials LadRx Corporation

Equities

LADX

US2328287071

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 15:19:16 2024-05-09 EDT 		5-day change 1st Jan Change
2.76 USD -8.00% Intraday chart for LadRx Corporation -8.00% +112.31%
03-27 LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
01-11 Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol DJ

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 15.1 9.755 63.84 19.58 5.179 0.6436
Enterprise Value (EV) 1 -6.277 -6.376 54.43 13.23 4.034 -1.393
P/E ratio -1.09 x -1.35 x -9.05 x -1.42 x -1.05 x 1.91 x
Yield - - - - - -
Capitalization / Revenue 60.4 x - - - - -
EV / Revenue -25.1 x - - - - -
EV / EBITDA 0.76 x 0.81 x -8 x -2.22 x -0.89 x 0.37 x
EV / FCF 0.52 x 1.9 x -15.4 x -4.91 x -1.22 x 0.88 x
FCF Yield 192% 52.6% -6.5% -20.4% -82% 113%
Price to Book 0.74 x 0.64 x 7.2 x 26 x -3.93 x 6 x
Nbr of stocks (in thousands) 336 336 365 388 450 495
Reference price 2 44.88 29.00 175.0 50.50 11.50 1.300
Announcement Date 19-03-29 20-03-27 21-03-24 22-03-23 23-03-20 24-03-27
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.25 - - - - -
EBITDA 1 -8.219 -7.841 -6.8 -5.966 -4.546 -3.812
EBIT 1 -8.248 -7.861 -6.829 -5.98 -4.561 -3.824
Operating Margin -3,299.25% - - - - -
Earnings before Tax (EBT) 1 -9.079 -7.522 -6.7 -13.18 -4.201 0.4004
Net income 1 -12.71 -7.163 -6.701 -13.18 -4.201 0.4004
Net margin -5,085.44% - - - - -
EPS 2 -41.08 -21.53 -19.34 -35.52 -10.98 0.6790
Free Cash Flow 1 -12.02 -3.354 -3.539 -2.696 -3.307 -1.58
FCF margin -4,809.37% - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-03-29 20-03-27 21-03-24 22-03-23 23-03-20 24-03-27
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 21.4 16.1 9.41 6.35 1.15 2.04
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -12 -3.35 -3.54 -2.7 -3.31 -1.58
ROE (net income / shareholders' equity) -47.2% -42.3% -55.7% -193% -175% 602%
ROA (Net income/ Total Assets) -14.5% -24.5% -29.1% -36% -52% -105%
Assets 1 87.89 29.29 23.01 36.64 8.085 -0.3816
Book Value Per Share 2 60.50 45.20 24.30 1.940 -2.930 0.2200
Cash Flow per Share 2 63.50 48.00 27.40 17.50 3.050 4.180
Capex 1 0.01 0.02 0.03 0.01 0 -
Capex / Sales 4.59% - - - - -
Announcement Date 19-03-29 20-03-27 21-03-24 22-03-23 23-03-20 24-03-27
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LADRX CORPORATION Stock LadRx Corporation
+112.31% 1.37M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. LADX Stock
  4. Financials LadRx Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW